Sustained-release drug delivery systems for the treatment of glaucoma

Kesav, Natasha; Young, Cara E Capitena; Ertel, Monica; Seibold, Leonard K.; Kahook, Malik Y.

doi:10.18240/ijo.2021.01.21

Cited by 30 publications

(28 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another delivery system developed with PRINT R is an Envisia Therapeutics implant (ENV515) currently in phase 2 clinical trials (194). Results thus far suggest that ENV515 is effective in lowering IOP for 28 days (195,196). Results from a 12-month study found 25% IOP reduction compared to topical ophthalmic solution (195).…”

Section: Fibers Films Rods Extrusionsmentioning

confidence: 97%

See 1 more Smart Citation

Considerations for Polymers Used in Ocular Drug Delivery

et al. 2022

View full text Add to dashboard Cite

PurposeAge-related eye diseases are becoming more prevalent. A notable increase has been seen in the most common causes including glaucoma, age-related macular degeneration (AMD), and cataract. Current clinical treatments vary from tissue replacement with polymers to topical eye drops and intravitreal injections. Research and development efforts have increased using polymers for sustained release to the eye to overcome treatment challenges, showing promise in improving drug release and delivery, patient experience, and treatment compliance. Polymers provide unique properties that allow for specific engineered devices to provide improved treatment options. Recent work has shown the utilization of synthetic and biopolymer derived biomaterials in various forms, with this review containing a focus on polymers Food and Drug Administration (FDA) approved for ocular use.MethodsThis provides an overview of some prevalent synthetic polymers and biopolymers used in ocular delivery and their benefits, brief discussion of the various types and synthesis methods used, and administration techniques. Polymers approved by the FDA for different applications in the eye are listed and compared to new polymers being explored in the literature. This article summarizes research findings using polymers for ocular drug delivery from various stages: laboratory, preclinical studies, clinical trials, and currently approved. This review also focuses on some of the challenges to bringing these new innovations to the clinic, including limited selection of approved polymers.ResultsPolymers help improve drug delivery by increasing solubility, controlling pharmacokinetics, and extending release. Several polymer classes including synthetic, biopolymer, and combinations were discussed along with the benefits and challenges of each class. The ways both polymer synthesis and processing techniques can influence drug release in the eye were discussed.ConclusionThe use of biomaterials, specifically polymers, is a well-studied field for drug delivery, and polymers have been used as implants in the eye for over 75 years. Promising new ocular drug delivery systems are emerging using polymers an innovative option for treating ocular diseases because of their tunable properties. This review touches on important considerations and challenges of using polymers for sustained ocular drug delivery with the goal translating research to the clinic.

show abstract

Section: Fibers Films Rods Extrusionsmentioning

confidence: 97%

“…Results thus far suggest that ENV515 is effective in lowering IOP for 28 days (195,196). Results from a 12-month study found 25% IOP reduction compared to topical ophthalmic solution (195). PRINT R shows great promise for its ability to customize polymer-based ocular drug delivery systems at the nanoscale level.…”

Section: Fibers Films Rods Extrusionsmentioning

confidence: 97%

Considerations for Polymers Used in Ocular Drug Delivery

et al. 2022

View full text Add to dashboard Cite

show abstract

“…A placebo-controlled multicentre Phase III trial found OTX-TP treated eyes had statistically significant IOP reduction in eight of nine time points over 20-weeks of follow-up, with only transient and minor adverse effects, most commonly dacyrocanaliculitis [ 106 ]. However, the system is reportedly no longer under development [ 107 ]. Other external routes recently considered have included topical forniceal inserts [ 108 ], subconjunctival injections [ 109 ], and micelle-laden contact lenses to achieve sustained drug release [ 110 ].…”

Section: Amd Dmo Rvo and Uveitismentioning

confidence: 99%

An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma

Ghanchi

Bourne

Downes

et al. 2022

Eye

View full text Add to dashboard Cite

In the real-world setting, there is suboptimal compliance with treatments that require frequent administration and assessment visits. This undertreatment frequently has negative consequences in eye disease and carries a real risk to vision. For example, patients with glaucoma risk progression of visual loss even with a small number of missed doses, and patients with neovascular age-related degeneration (nAMD) who fail to attend a bi-monthly clinic appointment to receive an intravitreal anti-vascular endothelial growth factor (VEGF) drug injections may lose the initial vision gains in vision. Protracted regular treatment schedules represent a high burden not only for patients and families, but also healthcare professionals, systems, and ultimately society too. There has been a clear need for longer-acting therapies that reduce the frequency, and therefore the burden, of treatment interventions. Several longer-acting interventions for nAMD, diabetic macular oedema, retinal vein occlusion, uveitis and glaucoma have either been developed or are in late-phase development, some of which employ novel mechanisms of actions, and all of which of promise longer (≥3 month) treatment intervals. This review delivers an overview of anti-VEGF agents with longer durations of action, DARPins, bispecific anti-VEGF/Ang2 therapies, anti-PDGF and anti-integrin therapy, Rho-kinase inhibitors, the Port Delivery System, steroids, gene therapy for retina and uveitis, and for glaucoma, ROCK inhibitors, implants and plugs, and SLT laser and MIGS. The review also refers to the potential of artificial intelligence to tailor treatment efficacy with a resulting reduction in treatment burden.

show abstract

“… 17 In addition, large doses and frequent systemic administration can cause adverse effects. 18 Recent studies have shown that nano-carriers are useful to deliver hydrophilic or lipophilic drugs to the eye, prolong the half-life of drugs in the vitreous, and improve the bioavailability of many drugs, including proteins and peptides. 19 , 20 Interestingly, applications of polymeric nano-micelles have been tested for intraocular and surface ocular disease treatment.…”

Section: Traditional Delivery Of Ocular Drugsmentioning

confidence: 99%

Ten Years of Knowledge of Nano-Carrier Based Drug Delivery Systems in Ophthalmology: Current Evidence, Challenges, and Future Prospective

Zhang¹,

Jiao²,

Niu³

et al. 2021

IJN

View full text Add to dashboard Cite

The complex drug delivery barrier in the eye reduces the bioavailability of many drugs, resulting in poor therapeutic effects. It is necessary to investigate new drugs through appropriate delivery routes and vehicles. Nanotechnology has utilized various nano-carriers to develop potential ocular drug delivery techniques that interact with the ocular mucosa, prolong the retention time of drugs in the eye, and increase permeability. Additionally, nano-carriers such as liposomes, nanoparticles, nano-suspensions, nano-micelles, and nano-emulsions have grown in popularity as an effective theranostic application to combat different microbial superbugs. In this review, we summarize the nano-carrier based drug delivery system developments over the last decade, particularly review the biology, methodology, approaches, and clinical applications of nano-carrier based drug delivery system in the field of ocular therapeutics. Furthermore, this review addresses upcoming challenges, and provides an outlook on potential future trends of nano-carrier-based drug delivery approaches in ophthalmology, and hopes to eventually provide successful applications for treating ocular diseases.

show abstract

Sustained-release drug delivery systems for the treatment of glaucoma

Cited by 30 publications

References 60 publications

Considerations for Polymers Used in Ocular Drug Delivery

Considerations for Polymers Used in Ocular Drug Delivery

An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma

Ten Years of Knowledge of Nano-Carrier Based Drug Delivery Systems in Ophthalmology: Current Evidence, Challenges, and Future Prospective

Contact Info

Product

Resources

About